76 results about "Peptide ligand" patented technology

Methods and apparatus for determining protein and ligand sequence, structure, and docking site given a target protein sequence and structure are presented. A multicapitate transformer architecture with a number of heads including a sequence head and a structure head is introduced, wherein given a target protein sequence and structure, a candidate ligand is generated, wherein the transformer's sequence head yields the ligand sequence and the structure head yields the ligand structure and docking site. Non-capitate weights are shared between the output heads. In one embodiment, a discriminative feature localization method is used to optimize the target protein's input structure representation towards the desired ligand effect class. The methods and apparatus presented enable design and synthesis of both peptide ligands and small molecule drugs each with specified ligand effect categories.

Methods and apparatus for determining a representation of a protein-protein complex, given a constituent target complex of the protein-protein complex are presented; where the constituent target complex is some subset of the protein-protein complex. A recursive transformer neural network is devised, wherein for each iteration of the recursion, a representation of the output constituent protein complexed with the input constituent target complex is passed into the transformer as input for the next iteration. Some embodiments of the invention include design and manufacturing of effective synthetic biologic drugs, monoclonal antibody (mAb) drug, Antibody Drug Conjugate (ADC), peptide ligand drug, and small molecule drugs (SMDs).

The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase – 1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.

The present disclosure provides materials and methods related to the purification of a biologic from a biological fluid. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production of a biologic.

The present invention relates to a heterotandem acyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, which is conjugated via a linker to a second peptide ligand that binds to a component present on a cancer cell. The present invention also relates to the use of said heterotandem acyclic peptide complex in preventing, inhibiting, or treating cancer.

The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production and purification of adeno-associated viruses (AAVs).

The invention discloses an affinity peptide ligand for separation and purification of a VSV-G pseudotype lentiviral vector and application of the affinity peptide ligand. The affinity peptide ligand contains an amino acid sequence combined with a VSV-G pseudotype lentiviral vector envelope protein; the amino acid sequence is any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7 and SEQ ID NO. 8. A biological raw material solution containing VSV-G pseudotype lentivirus vector components flows into the affinity chromatography medium, and after adsorption and cleaning, a target vector can be collected through a mild elution step; the recovery rate of virus vector particles is 78% or above, the removal rate of Vero host cell impure protein is 90% or above, the double-stranded DNA residue is 48% or below, and the separation effect is very remarkable.

Methods for determining a representation of a protein complex, given a constituent target complex of that protein complex are presented; where the constituent target complex is a single entity constituent or subcomplex of the protein complex; and wherein a protein complex is a complex of some combination of one or more of proteins, nucleic acids, metal ions, and small molecules. A recursive neural network is devised, wherein for each iteration of the recursion, a representation of the output constituent of the protein complex together with the input constituent target complex is passed into the neural network as input for the next iteration. Some embodiments of the invention include design and manufacturing of effective synthetic biologic drugs, monoclonal antibody (mAb) drug, Antibody Drug Conjugate (ADC), peptide ligand drug, and small molecule drugs (SMDs).

The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

To provide a ligand binding to nectin-4 present on cancer cells, or a pharmaceutically acceptable salt thereof.SOLUTION: The present invention relates to heterotandem bicyclic peptide complexes comprising a first peptide ligand that binds to a component present on a cancer cell conjugated via a linker to a second peptide ligand that binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in the prevention, inhibition or treatment of cancer.SELECTED DRAWING: None

The present disclosure provides compositions and methods related to the purification and / or isolation of antibodies. In particular, the present disclosure provides novel peptide ligands capable of targeting the fragment antigen binding (Fab) domain and / or single-chain variable fragment (scFv) of antibodies to facilitate the isolation and / or purification of antibodies from processing fluid streams. The novel ligands disclosed herein are capable of universal and subtype-specific biorecognition.

The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue via 18F-labeled peptide ligands disclosed herein.

To provide a new conjugate usable for photoimmunotherapy.SOLUTION: The conjugate of the present disclosure comprises an epidermal growth factor receptor (EGFR) peptide ligand and a photosensitive dye, wherein said photosensitive dye is conjugated to said EGFR peptide ligand via a linker, wherein the backbone length of said linker is between 14 and 55 atoms.SELECTED DRAWING: Figure 5

The application discloses a biased polypeptide ligand of protease-activated receptor 2 and application thereof, and belongs to the technical field of proteins and polypeptides. The application aims to provide a biased polypeptide ligand of protease-activated receptor 2, which only activates the Gq signal pathway of PAR2. The application provides a biased polypeptide ligand of protease-activated receptor 2, which is obtained by any one or both of mutation and modification of amino acids of SLIGRL-NH2 as a starting sequence. The biased PAR2 polypeptide ligand designed in the application has unique advantages in treating diseases caused by nerve injury.

The invention relates to the technical field of chemical synthesis of medicines, in particular to a peptide compound, a peptide ligand, a peptide complex and application thereof. The peptide compound as well as the peptide ligand and the peptide complex thereof provided by the invention have remarkable uPAR targeting specificity and excellent uPAR affinity, which indicates that the peptide compound, the peptide ligand and the peptide complex can act on related diseases with high uPAR expression, or can be used as carriers to carry nuclides to be accurately delivered to tumor sites, so that the treatment effect is improved. The peptide compounds, the peptide ligands and the peptide complexes have the advantages that uPAR targeting specificity is remarkable, and a novel clinical solution is provided for accurate diagnosis and treatment of uPAR high-expression tumors.

The application discloses a polypeptide ligand SR-22 targeting a membrane protein of a pathogenic oomycete and an application thereof, and the amino acid sequence of the polypeptide ligand SR-22 is SRITRLLRGSGSGSSRITRLLR. The polypeptide ligand SR-22 provided by the application can significantly inhibit the growth of various crop pathogenic oomycetes, and can well inhibit the infection of pathogenic bacteria and prevent the occurrence of diseases in practical application, and can be developed into a novel targeted polypeptide pesticide for green prevention and control of crop oomycete diseases.

The application discloses a broad-spectrum affinity peptide ligand for influenza vaccine separation and purification and application thereof. The broad-spectrum affinity peptide ligand contains an amino acid sequence which is combined with the conserved structural units 130-loop, 150-loop and 190-helix of the hemagglutinin receptor binding site of an influenza virus, and the amino acid sequence is R 1 -R 2 -R 3 -(R 4 )3-R 5 -(R 4 )2-R 6 -R 7 -R 8 , R 1 is any one of glutamic acid, arginine, histidine and proline, R 2 is tryptophan, R 3 is any one of tyrosine and phenylalanine, R 4 is glycine, R 5 is any one of tryptophan, tyrosine and phenylalanine, R 6 is any one of glutamic acid, histidine, glutamine and tyrosine, R 7 is any one of tryptophan and phenylalanine, and R 8 is proline. The broad-spectrum affinity peptide ligand has high broad-spectrum affinity, and the broad-spectrum affinity chromatography medium can obtain the influenza vaccine with high purity and yield, and has great potential in application to the separation and purification process of the influenza vaccine.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1.

Provided herein are selectin-binding peptide ligands having both D- and L-amino acids, and peptide conjugates including the provided peptide ligands. The peptide conjugates can include a biopolymer backbone, such as dermatan sulfate, and 33 or fewer peptide ligands conjugated to the biopolymer. Also provided are methods for using the provided peptide conjugates to treat patients suffering from endothelial dysfunction.

The invention relates to the technical field of biology, in particular to a p53 protein targeting inhibitor and a design method thereof. The molecular mechanism and microscopic details of interaction of azurin-p53 protein complexes are analyzed through an MD simulation technology and an MM-PBSA free energy decomposition method, key binding sites between the complexes and spatial distribution of the key binding sites are determined, and an affinity model is established, so that a candidate affinity ligand peptide library is constructed. Then, screening and verifying the affinity ligand library through methods of molecular docking, conformation analysis, binding site comparison, hydrophobicity analysis, MD simulation and the like to obtain a high-affinity ligand aiming at a p53 protein target spot, and verifying the binding performance of the affinity peptide ligand and the p53 protein through a double-antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) experiment. And screening to obtain the p53 protein inhibitory peptide with high affinity with the p53 protein.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also relates to pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).

This invention discloses a class of polypeptide ligands that can specifically bind to and / or significantly promote the assembly of Holliday linkers and their applications, belonging to the field of biomedical technology. The general formula for the amino acid sequence of the polypeptide ligand is: AX₄BQX₃CXn, where A and B are each independently selected from any one of phenylalanine, tryptophan, tyrosine, lysine, and arginine; C is selected from any one of arginine and lysine; X represents any amino acid; and n is an integer ranging from 0 to 4. The advantages of this invention are: the polypeptide provided by this invention has a high affinity for Holliday linkers (HJs), a strong ability to promote HJ formation, and exhibits certain antitumor activity against human liver cancer cells A549.

The application relates to a method for generating a target AAV9 antibody epitope affinity peptide ligand by using a protein language model and a screening method and application thereof, and relates to an affinity peptide candidate sequence construction and screening method, an affinity peptide ligand, an affinity medium and application thereof for targeting adeno-associated virus type 9 (AAV9). The AAV9 capsid region recognized by Fab2-4 is taken as a target, structure analysis, natural amino acid positioning, key residue extraction and affinity peptide template construction are carried out, a candidate peptide library is generated by using a protein language model, and a candidate affinity peptide ligand is screened by combining molecular docking, binding free energy evaluation, refined docking and molecular dynamics simulation. The affinity peptide ligand is any one of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4, can be immobilized on a solid phase matrix to form an affinity medium, is used for AAV9 recognition, capture and purification, and provides a technical scheme for AAV9 purification process development.

The present invention relates to an antiviral use of a novel peptide binding specifically to nucleolin and, more specifically, to: an antiviral composition comprising a peptide represented by a specific amino acid sequence; an antiviral composition comprising a fusion peptide in which the peptide and a cell-penetrating peptide are coupled to each other; a composition comprising the aforementioned compositions for preventing or treating a viral infection; and a health functional food composition for prevention or alleviation of a viral infection. In the present invention, a AGM peptide ligand and mutants thereof were found to inhibit viral proliferation and replication (in vitro and in vivo), as screened by an MAP synthesis method and an OBOC combination method. Therefore, NCL-targeting AGM can find advantageous applications in antiviral uses.

A computer-implemented method for identifying an amino acid sequence that is predicted to form a scaffold-binding peptide ligand that binds to a target, the method comprising: generating an amino acid sequence that describes a peptide, the sequence satisfying one or more predefined sequence constraints such that the peptide binds to one of one or more predefined scaffolds at at least two positions, thereby forming a scaffold-binding peptide ligand; determining at least one predicted interaction characteristic associated with an interaction between the peptide and one or more predefined targets; determining an advantage of the at least one predicted interaction characteristic; based on the determined advantageous, output data is provided that identifies one or more amino acid sequences that are predicted to form scaffold-binding peptide ligands that bind to the target.

The application provides a structure-based evaluation model for equilibrium dissociation constant of a peptide ligand molecule and a target protein, comprising: obtaining of peptide ligand equilibrium dissociation constant data; obtaining of peptide ligand and receptor protein interaction relationship characteristic data; data set for algorithm system construction: construction of a targeting IgG series polypeptide characteristic library and a targeting alpha beta 42 series polypeptide characteristic library, and construction of an independent verification data set; using the targeting IgG series polypeptide characteristic library to construct a machine learning algorithm classifier system, optimizing related parameters, testing by using the targeting alpha beta 42 series polypeptide characteristic library, and evaluating system performance; and evaluating actual prediction performance of the system by using the constructed related independent data set. The application uses a virtual screening method to study a peptide ligand and a target protein interaction region, which can further improve drug screening efficiency and reduce corresponding cost.

The present invention relates to polypeptides which are covalently bound to non-aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the Eph receptor tyrosine kinase A2 (EphA2). The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder characterised by overexpression of EphA2 in diseased tissue (such as a tumour).